NCT07000149 2026-03-10
eVOLVE-RCC02
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
7 trialsNCT03203473 2026-02-06
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05239533 2026-01-14
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03693014 2025-10-06
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
NCT05215470 2024-07-03
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
Hospital das ClÃnicas de Ribeirão Preto
Phase 2 Active not recruiting
NCT02293980 2024-06-17
MK-3795-001
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1 Active not recruiting